Speculative Plans Are Insufficient to Establish Standing in PTAB Appeals
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Nathan D. Reeves and Ningxi Sun
INCYTE CORPORATION v. SUN PHARMACEUTICAL INDUSTRIES, INC.
Before Moore, Hughes, and Cunningham. Appeal from the Patent Trial and Appeal Board.
Summary: Speculative plans for potentially infringing activity are insufficient to establish Article III standing to appeal the Board’s decision.
Incyte filed a petition for post-grant review of Sun’s patent covering a compound for treating hair loss. The PTAB found Incyte failed to prove unpatentability. Incyte appealed, and argued that it had standing based on potential infringement liability and the competitor standing doctrine.
The Federal Circuit held Incyte failed to establish an injury in fact sufficient to confer standing. Regarding potential infringement liability, the court found that Incyte failed to demonstrate concrete plans to develop and market a product that would create a substantial risk of future infringement. Rather, Incyte’s development plans were too speculative. For example, the amount of money spent was small and was spread across several related products, some of which would not create a risk of infringement, and Incyte did not identify what portion of its allocated funding was directed toward developing a product covered by the claims. The court also rejected Incyte’s competitor-standing argument because that doctrine also requires a showing of concrete injury.
Editor: Sean Murray
More insights
PTAB in 2026: What Practitioners Are Getting Wrong
Institution rates have moved, but the reasoning behind them has moved further. The number most petitions still cite is the headline institution rate — and it has not been the operative number for two years. The two stage problem A petition now has to…
Fresh From the Bench: Latest Precedential Patent Case
Ridge Corp. et al. v. Kirk NationaLease Co. et al. , Appeal No. 2025-1254 (Fed. Cir. July 13, 2026) In its only precedential patent opinion last week, the Federal Circuit considered an appeal of a preliminary injunction issued by the U.S. District Court…
Fresh From the Bench: Latest Precedential Patent Cases
CASE OF THE WEEK Wyeth LLC v. AstraZeneca Pharmaceuticals LP , Appeal No. 2024-2325 (Fed. Cir. July 9, 2026) In our Case of the Week, the Federal Circuit affirmed a district court ruling reversing a $107.5 million jury verdict against AstraZeneca in a case…